In this episode, we review long-term medication therapy for CAD, including medications used post-myocardial infarction (MI) and medications used for anginal symptom relief in unrevascularizable CAD. What pathways do colchicine interrupt in the development of CAD? Is dual-antiplatelet therapy (DAPT) primarily for prevention of in-stent thrombosis or in-stent restenosis? How many months should you continue DAPT after percutaneous coronary intervention (PCI) for acute coronary syndrome versus after PCI for chronic coronary disease? In which post-MI patients should beta blockers, ACE inhibitors/ARBs, and statins be added? Among the anti-anginal medications beta blockers, nitrates, calcium channel blockers, and ranolazine, which single class has a mortality benefit instead of just a symptom benefit? Tune in for answers to these questions.

Difficulty Level: Easy

You are listening to Hu Said: Cardiology Board Review Series (2024-2025 Season)

Please subscribe, rate, and support the channel! Ads help keep materials free for everyone.

More MedEd resources available at ⁠⁠www.rueyhu.com⁠⁠

Updates at Twitter/X: ⁠⁠@Ruey_Hu⁠